This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chamuleau, M. E. D. Articles by Ossenkoppele, G. J. Search for Related Content PubMed PubMed Citation Articles by Chamuleau, M. E. D. Articles by Ossenkoppele, G. J.

Class II-Associated Invariant Chain Peptide Expression on Myeloid Leukemic Blasts Predicts Poor Clinical Outcome

Departments of ¹ Hematology, ² Clinical Epidemiology and Biostatistics, and ³ Pathology, VU University Medical Center, Amsterdam, the Netherlands; ⁴ Division of Tumor Biology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; ⁵ Department of Immunopathology, Sanquin Research at Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam, the Netherlands

Effective antitumor responses need the activation of CD4+ T cells. MHC class II antigen presentation requires the release of class II-associated invariant chain peptide (CLIP) from the antigen-binding site. In antigen-presenting cells, human leukocyte antigen DM (HLA-DM; abbreviated DM in this article) catalyzes CLIP dissociation. In B cells, HLA-DO (DO) down-modulates DM function. Cell surface CLIP:HLA-DR (DR) ratio correlates to DO:DM ratio and the efficacy of antigen presentation. We examined 111 blood and bone marrow samples of patients with newly diagnosed acute myeloid leukemia (AML) for the expression of CLIP, DR, DM, and DO by flow cytometry. Patients with DR+/CLIP– blasts had a significant longer disease-free survival than patients with DR+/CLIP+ blasts. DO, until now believed to be restricted to lymphoid cells, could be demonstrated at protein level as well as by reverse transcription-PCR. DO:DM ratio correlated to CLIP:DR ratio, suggesting that, unlike in other antigen-presenting cells of the nonlymphoid cell type, both DO and DM mediate regulation of CLIP expression in AML blasts. We hypothesize that DR+/CLIP– AML blasts are able to present leukemia-specific antigens to CD4+ T helper cells initiating an effective and long-lasting antitumor response resulting in a prolonged disease-free survival.

This article has been cited by other articles:

				R. Stein, M. J. Mattes, T. M. Cardillo, H. J. Hansen, C.-H. Chang, J. Burton, S. Govindan, and D. M. Goldenberg CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms Clin. Cancer Res., September 15, 2007; 13(18): 5556s - 5563s. [Abstract] [Full Text] [PDF]

				M. E. Chamuleau, N. Feller, A. Kelder, A. A. Van de Loosdrecht, and G. J. Ossenkoppele High CLIP (Class II Associated Invariant Chain Peptide) Expression on Minimal Residual Disease Cells Is Associated with High Relapse Rate in AML Patients. Blood (ASH Annual Meeting Abstracts), November 1, 2006; 108(11): 2300 - 2300. [Abstract] [PDF]

				S. A. Oldford, J. D. Robb, D. Codner, V. Gadag, P. H. Watson, and S. Drover Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients Int. Immunol., November 1, 2006; 18(11): 1591 - 1602. [Abstract] [Full Text] [PDF]

				N. Boissel, P. Rousselot, E. Raffoux, J.-M. Cayuela, J. Soulier, N. Mooney, D. Charron, H. Dombret, A. Toubert, and D. Rea Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation J. Leukoc. Biol., April 1, 2006; 79(4): 747 - 756. [Abstract] [Full Text] [PDF]

				T. M. C. Hornell, T. Burster, F. L. Jahnsen, A. Pashine, M. T. Ochoa, J. J. Harding, C. Macaubas, A. W. Lee, R. L. Modlin, and E. D. Mellins Human Dendritic Cell Expression of HLA-DO Is Subset Specific and Regulated by Maturation J. Immunol., March 15, 2006; 176(6): 3536 - 3547. [Abstract] [Full Text] [PDF]

				J. A. Thompson, S. K. Dissanayake, B. R. Ksander, K. L. Knutson, M. L. Disis, and S. Ostrand-Rosenberg Tumor Cells Transduced with the MHC Class II Transactivator and CD80 Activate Tumor-Specific CD4+ T Cells Whether or Not They Are Silenced for Invariant Chain Cancer Res., January 15, 2006; 66(2): 1147 - 1154. [Abstract] [Full Text] [PDF]